Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
In Vivo is Scopus-indexed (Q2, CiteScore 3.3), WoS SCIE. Published by International Institute of Anticancer Research.
Checked against the index lists dated .
ISSN 0258-851XVerify ISSN ↗1791-7549Verify ISSN ↗
Publisher: International Institute of Anticancer Research
Cost to publish: No APC data — check the publisher
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Biochemistry, Genetics and Molecular Biology (all) | 111 / 223 | 50th | Q2 |
| Pharmacology | 203 / 328 | 38th | Q3 |
| Cancer Research | 173 / 233 | 25th | Q3 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 1987–present, best quartile Q2, CiteScore 3.3.
In Vivo is Q2 in Biochemistry, Genetics and Molecular Biology (all) (rank 111 of 223), Q3 in Pharmacology (rank 203 of 328) and Q3 in Cancer Research (rank 173 of 233), by CiteScore 2025.
In Vivo is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 3.3, which places it in quartile Q2 at the 50th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.536, quartile Q2, with an H-index of 77.
In Vivo is published by International Institute of Anticancer Research. Its print ISSN is 0258-851X and its online ISSN is 1791-7549.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
In Vivo has an h-index of 56 and a 2-year mean of 1.79 citations per paper (OpenAlex). Its Scopus CiteScore is 3.3, quartile Q2. On 2-year citations it ranks #110 of 221 Scopus journals in Biochemistry, Genetics and Molecular Biology (all).
In Vivo published 305 papers in 2025; its busiest recent year was 2021 with 509. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 98 research articles (2026), authors are most often from Japan (50%), Taiwan (12.2%) and Germany (7.5%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 8 retracted papers are recorded (2.3 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.